Neuroscientific Biopharmaceuticals Ltd. (NSB) AI Stock Analysis

• Market Cap: AU$28.60M
• Dividend Yield: N/A
• Average Volume (3M): 306.60K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.78
• Revenue Growth: N/A
• EPS Growth: -672.73%
• Country: AU
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): >-0.01
• Shares Outstanding: 332,575,700
• 10 Day Avg. Volume: 291,172
• 30 Day Avg. Volume: 306,603
• PEG Ratio: 0.01
• Price to Book (P/B): 0.76
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -13.54
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 40 Underperform
• Price Target: AU$0.08 ▼(-16.00% Downside)
• Action: Downgraded Date: 02/25/26
• Date: Action: Downgraded 02/25/26

The score is held down primarily by weak financial performance (revenue collapse, persistent losses, and negative free cash flow) and bearish technical signals (price below major moving averages and negative MACD). A debt-free balance sheet provides some resilience, but losses and cash burn remain the dominant risk, while valuation offers limited support due to negative earnings and no dividend.

Positive Factors

Debt-free balance sheet

Zero reported debt materially reduces solvency and interest burden risk for an R&D-heavy biotech. This durable strength lengthens strategic optionality, easing downside during funding cycles and enabling management to pursue partnerships or milestone funding without creditor pressure.

Positive equity backing assets

Sustained positive equity and equity-funded assets provide a buffer against operating losses and support continued R&D spending. This balance-sheet composition improves resilience versus leveraged peers and preserves room for non-debt strategic moves like licensing or equity-linked partnerships.

Focused neuroscience R&D pipeline

A clear strategic focus on neuroscience therapeutics creates a concentrated development thesis. Structural unmet needs in the therapeutic area mean successful clinical progress can produce durable, high-value outcomes; sustained R&D focus aligns resources to capture those binary value events.

Negative Factors

Revenue collapse and volatility

Revenue collapsing to zero in 2025 and prior volatility remove topline predictability, undermining any near-term commercial sustainability. Lack of recurring sales forces dependence on milestone payments or financing, increasing execution and financing risk over the medium term.

Persistent negative cash flow

Consistent negative operating and free cash flows, with a sharp 2025 deterioration, indicate structural cash burn. This elevates the need for external funding or dilutive equity raises, stressing long-term capital structure and creating ongoing execution risk absent clear funding plans.

Recurring operating losses

Large, recurring operating losses and negative EBITDA across reporting periods show no current path to operational profitability. For an early-stage biotech this heightens reliance on binary R&D outcomes and financing, limiting reinvestment capacity and increasing the risk of dilution or strategic compromises.

Neuroscientific Biopharmaceuticals Ltd. Business Overview & Revenue Model

Company Description

NeuroScientific Biopharmaceuticals Limited develops therapeutic treatments for neurodegenerative diseases through preclinical and clinical studies of patented technologies. Its lead drug candidates include EmtinB for treatment of neurodegenerative dementia and Alzheimer's disease, and degenerative conditions of the optic nerve. The company was incorporated in 2002 and is based in Cottesloe, Australia.

How the Company Makes Money

null

Neuroscientific Biopharmaceuticals Ltd. Financial Statement Overview

Summary

Overall financial quality is weak: revenue volatility includes a collapse to zero in 2025, profitability remains poor with recurring operating losses, and cash flow shows ongoing cash burn with negative operating and free cash flow in most years. The main offset is a stronger balance sheet with zero reported debt and positive equity, which reduces solvency risk but does not solve funding needs if losses persist.

Income Statement

Revenue has been highly volatile and recently collapsed to zero in 2025 (annual), following declines from 2023 to 2024. Profitability is weak: the company posted large operating losses across the period (negative EBIT/EBITDA every year shown), and 2025 returned to a sizable net loss after a small net profit in 2024. Overall, the income statement reflects a business still in heavy investment mode with limited visibility to consistent revenue generation.

Balance Sheet

The balance sheet is a relative strength: total debt is reported as zero across all periods, reducing financial risk and interest burden. Equity remains positive, and total assets are largely equity-funded; however, equity levels have been volatile (notably higher in 2021 and 2025 vs. 2023–2024), and returns on equity are mostly negative due to recurring losses (except 2024). Net-net, solvency looks solid, but shareholder value creation is inconsistent.

Cash Flow

Cash generation is weak and inconsistent. Operating cash flow and free cash flow are negative in most years (including a sharp deterioration in 2025), with only a modest positive year in 2024. The pattern suggests ongoing cash burn typical of early-stage biotech, increasing funding dependence despite low balance-sheet leverage.

Breakdown	Jun 2025	Jun 2024	Jun 2023	Jun 2022	Jun 2021
Income Statement
Total Revenue	0.00	2.21M	4.95M	0.00	958.77K
Gross Profit	-92.78K	-91.34K	-57.85K	-64.92K	897.36K
EBITDA	-1.92M	-1.80M	-5.96M	-10.37M	-3.12M
Net Income	-1.85M	324.21K	-1.07M	-10.44M	-3.18M
Balance Sheet
Total Assets	16.96M	5.44M	5.29M	7.74M	14.83M
Cash, Cash Equivalents and Short-Term Investments	7.27M	4.95M	4.91M	7.22M	14.16M
Total Debt	0.00	0.00	0.00	0.00	0.00
Total Liabilities	149.22K	85.68K	597.36K	2.22M	223.41K
Stockholders Equity	16.81M	5.35M	4.69M	5.52M	14.60M
Cash Flow
Free Cash Flow	-941.33K	42.43K	-2.30M	-6.95M	-2.63M
Operating Cash Flow	-941.33K	44.25K	-2.30M	-6.94M	-2.60M
Investing Cash Flow	-36.04K	-1.81K	0.00	-3.87K	-29.88K
Financing Cash Flow	3.29M	0.00	0.00	0.00	13.51M

Neuroscientific Biopharmaceuticals Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.10
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:NSB, the sentiment is Negative. The current price of 0.1 is below the 20-day moving average (MA) of 0.10, below the 50-day MA of 0.12, and below the 200-day MA of 0.14, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 18.65 is Positive, neither overbought nor oversold. The STOCH value of 5.70 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:NSB.

Neuroscientific Biopharmaceuticals Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CYP	56 Neutral	AU$75.99M	-7.57	-179.37%	―	―	16.61%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SPL	50 Neutral	AU$193.16M	27.58	-15.96%	―	-40.74%	-21.21%
ILA	43 Neutral	AU$119.38M	-5.66	-100.58%	―	―	26.38%
PTX	42 Neutral	AU$58.88M	-5.28	-62.49%	―	―	10.78%
NSB	40 Underperform	AU$28.60M	-5.38	-19.10%	―	―	-672.73%
ADO	40 Underperform	AU$32.70M	-10.60	-142.30%	―	110.44%	35.90%

Neuroscientific Biopharmaceuticals Ltd. Corporate Events

NeuroScientific scales up StemSmart manufacturing with Q-Gen for Phase 2 trials

NeuroScientific Biopharmaceuticals has started the first technology transfer manufacturing run for its StemSmart mesenchymal stem cell therapy at Q-Gen Cell Therapeutics in Brisbane. The move shifts StemSmart’s patented manufacturing process to a large-scale GMP contract manufacturer with the capacity to supply product for Phase 2 clinical trials and future commercial demand.

Q-Gen, one of Australia’s largest cell therapy manufacturers with 13 dedicated cleanrooms and a TGA licence, is working through a six-stage transfer program, including process mapping, engineering runs and regulatory audit. Completion of the transfer and validation is targeted for the second half of 2026, aligning with NSB’s planned Phase 2 trial initiation and laying the groundwork for entry into the roughly US$13 billion global Crohn’s disease market.

The partnership is intended to secure a robust, regulatory-compliant supply chain for StemSmart and supports the company’s broader commercialisation strategy. By scaling up manufacturing and integrating NSB’s technology into Q-Gen’s quality systems, the company aims to position StemSmart as a platform cell therapy across multiple inflammatory conditions, potentially strengthening its competitive standing in advanced cell therapeutics.

The most recent analyst rating on (AU:NSB) stock is a Sell with a A$0.09 price target. To see the full list of analyst forecasts on Neuroscientific Biopharmaceuticals Ltd. stock, see the AU:NSB Stock Forecast page.

NeuroScientific Revenue Surges but Half-Year Loss Deepens and Asset Base Shrinks

NeuroScientific Biopharmaceuticals Limited reported its Appendix 4D results for the half-year ended 31 December 2025, highlighting a 359% increase in revenue from ordinary activities to $436,301 compared with the prior corresponding period. Despite the revenue growth, the company posted a loss from ordinary activities and overall loss attributable to owners of $1,699,413, up 362% year on year, did not declare a dividend for the half-year, and reported a fall in net tangible assets per share to 1.98 cents from 3.23 cents, underscoring ongoing investment and balance sheet pressure typical of early-stage biopharmaceutical firms.

The interim financial statements for the half-year were reviewed by the company’s auditors, with the review report included in the interim financial report released to the market. The results, signed off by chairman Rob McKenzie on 25 February 2026, signal that while NeuroScientific is generating higher operating revenue, it remains loss-making and reliant on its asset base to fund continuing development, a key consideration for shareholders monitoring dilution risk and future capital needs.

The most recent analyst rating on (AU:NSB) stock is a Hold with a A$0.12 price target. To see the full list of analyst forecasts on Neuroscientific Biopharmaceuticals Ltd. stock, see the AU:NSB Stock Forecast page.

NeuroScientific Advances StemSmart™ Program as Crohn’s Trial Prep Gathers Pace

NeuroScientific Biopharmaceuticals has advanced clinical and operational development of its StemSmart™ mesenchymal stem cell platform during the December 2025 quarter, with a particular focus on treating patients with severe, treatment-resistant fistulising Crohn’s disease through Australia’s Special Access Scheme. The company reported that three of four patients in the first cohort achieved a clinical response, providing early validation of the technology and informing the design of a planned Phase 2 trial in refractory Crohn’s disease expected to start in 2026. In parallel, NeuroScientific has appointed a Clinical & Scientific Advisory Board, progressed manufacturing technology transfer and scale-up with Q-Gen to bolster future clinical and supply readiness, and ended the quarter with approximately $6.4 million in cash, supporting its near-term clinical development plans and reinforcing its positioning as an emerging player in advanced cell therapies for inflammatory bowel disease.

The most recent analyst rating on (AU:NSB) stock is a Hold with a A$0.14 price target. To see the full list of analyst forecasts on Neuroscientific Biopharmaceuticals Ltd. stock, see the AU:NSB Stock Forecast page.

NeuroScientific’s StemSmart Therapy Delivers Strong Results in Fistulising Crohn’s Patients

NeuroScientific Biopharmaceuticals reported that three of four patients with fistulising Crohn’s disease treated with its patented StemSmart™ mesenchymal stem cell therapy under Australia’s Special Access Scheme achieved a successful clinical response, while the fourth patient showed a partial response with ongoing assessment. The strong outcomes in this hard-to-treat patient group are being used to shape the design of later-phase clinical trials expected to begin in the second half of 2026, underpin Phase 2 start-up activities including commercial manufacturing and regulatory planning, and support the company’s strategy to establish a foothold in the multibillion-dollar global Crohn’s disease market while expanding StemSmart™ as a broader platform therapy for chronic inflammatory indications.

The most recent analyst rating on (AU:NSB) stock is a Hold with a A$0.10 price target. To see the full list of analyst forecasts on Neuroscientific Biopharmaceuticals Ltd. stock, see the AU:NSB Stock Forecast page.